Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-10-04
2009-08-25
Haddad, Maher M (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
Reexamination Certificate
active
07579001
ABSTRACT:
The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.
REFERENCES:
patent: 6207642 (2001-03-01), Wiley
patent: 6727225 (2004-04-01), Wiley
patent: 6824773 (2004-11-01), Wiley
patent: 7169387 (2007-01-01), Rennert
patent: 2002/0004041 (2002-01-01), Albert et al.
patent: 2002/0042368 (2002-04-01), Fanslow et al.
patent: 2002/0110853 (2002-08-01), Wiley
patent: 2003/0162712 (2003-08-01), Cerretti et al.
patent: 2003/0170228 (2003-09-01), Ashkenazi et al.
patent: 2003/0198640 (2003-10-01), Yu et al.
patent: 2003/0211096 (2003-11-01), Ashkenazi et al.
patent: 2003/0211993 (2003-11-01), Jakubowski et al.
patent: 2003/0216546 (2003-11-01), Tykocinski
patent: 2004/0014176 (2004-01-01), Ashkenzai et al.
patent: 2004/0018170 (2004-01-01), Shirwan
patent: 2004/0033225 (2004-02-01), Browning et al.
patent: 2004/0047854 (2004-03-01), Black et al.
patent: 2004/0091473 (2004-05-01), DuBose et al.
patent: 2005/0112666 (2005-05-01), Browning et al.
patent: 2005/0118629 (2005-06-01), Browning et al.
patent: WO 98/05783 (1998-02-01), None
patent: WO 98/35061 (1998-10-01), None
patent: WO 98/55508 (1998-12-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/19490 (1999-04-01), None
patent: WO 99/61471 (1999-12-01), None
patent: WO 00/37638 (2000-06-01), None
patent: WO 01/45730 (2001-06-01), None
patent: WO 01/53486 (2001-07-01), None
patent: WO 03/086311 (2003-10-01), None
Zhao et al. TWEAK/Fn14 Interactions Are Instrumental in the Pathogenesis of Nephritis in the Chronic Graft-versus-Host Model of Systemic Lupus erythematosus. The Journal of Immunology, 2007, 179:7949-7958.
U.S. Appl. No. 09/169,104, filed Oct. 9, 1998, Askenazi et al.
U.S. Appl. No. 09/245,198, filed Feb. 5, 1999, Chicheportiche et al.
Abbas AK et al. “General Properties of Immune Responses”, Introduction to Immunology, pp. 4-12 inCellular and Molecular Immunology, Chapter One, (eds). Philadelphia: WB Saunders Co. (1991).
Abbas AK et al. (eds). “Immunity to Microbes”, pp. 302-314 inCellular and Molecular Immunology, Chapter Fifteen, Philadelphia: WB Saunders Co. (1991).
Ashkenazi and Dixit, “Death Receptors: Signaling and Modulation”, Science, vol. 281, pp. 1305-1308 (1998).
Bach-Elias et al., “Presence of autoantibodies against small nuclear ribonucleoprotein epitopes in Chagas' patients' sera”, Parasitol. Res., vol. 84, pp. 196-799 (1998).
Browning et al, “Characterization of surface lymphotoxin forms” J. Immunol, 154:33-46 (1995).
Boucraut et al., “Anti-TWEAK monoclonal antibodies reduces CNS immune cell infiltration and severity of experimental autoimmune encephalomyselitis”, Autoimmunity: Mechanisms and Novel Treatments, Myconos (Greece), Oct. 8-13, 2003, Abstract No. 64.
Cassiano et al. “Molecular Cloning of a Novel Receptor for TWEAK” Scand. J. Immunol. 51 (Supp. 1) 1-111.
Chaplin and Fu, “Current Opinion in Immunology”, vol. 10, pp. 288-297 (1998).
Chicheportiche et al. “Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory Pathologies.” Biochem Biophys Res Commun. Dec. 9, 2000;279(1):162-5.
Chicheportiche et al. “Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies.” Arthritis Res. 2002;4(2):126-33, Epub Nov. 9, 2001.
Chicheportiche et al., “TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family that Weakly Induces Apoptosis”, J. of Biological Chemistry, 272(51): 32401-32410 (1997).
Dallman, “Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult”, Immunology, vol. 7, pp. 632-638 (1995).
Desplat-Jego et al. “Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis”, Clinical Immunology, vol. 117, pp. 15-23 (2005).
Desplat-Jego et al. “Tweak is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J. Neuroimmunol”, Dec. 2002; 133 (1-2): 116-23.
De Wit et al., “Preferential Activation of Th2 Cells in Chronic Graft-versus-Host Reaction”, The Journal of Immunology, col. 150(2), pp. 361-366 (1993).
Durie et al., “Antibody to the Ligand of CD40, gp39, Blocks the Occurrence of the Acute and Chronic Forms of Graft-vs-Host Disease”, J. Clin. Invest., vol. 94, pp. 1333-1338 (1994).
Flynn et al., “CD4 T Cell Cytokine Differentiation: The B Cell Activation Molecule, OX40 Ligand, Instructs CD4 T Cells to Express Interleukin 4 and Upregulates Expression of the Chemokine Receptor, Blr-1”, J. Exp. Med., vol. 188, pp. 297-304 (1998).
Grewal and Flavell, “The CD40 Ligand”, Immunol. Res., vol. 16, pp. 59-70 (1997).
Grewal and Flavell, “The Role of CD40 Ligand in Costimulation and T-Cell Activation”, Immunol. Rev., vol. 153, pp. 85-106 (1996).
Jakubowski, (2000), Scand. J. Immunol., 51:Sup. 1:62.
Jakubowski, (2002), J. Cell Science, “Dual Role for TWEAK in angiogenic regulation” 115:267-274.
Kalled et al., “Anti-CD40 Ligand Antibody Treatment of SNF1Mice with Established Nephritis: Preservation of Kidney Function”, J. Immunol., vol. 160, pp. 2158-2165 (1998).
Kaplan et al. (1998) J. of Investigative Medicine, vol. 46:287A.
Kornek et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J. Pathol. Jul. 2002; 157(1): 267-76.
Krenger and Farrara, “Graft-versus-Host Disease and the Th1/Th2 Paradigm”, Immunol. Res., vol. 15, pp. 50-73 (1996).
Kirk et al., “CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates”, Proc. Natl. Acad. Sci. USA, vol. 94 , pp. 8789-8794 (1997).
Lenchow et al., “Differential Effects of Anti-B7-1 and Anti-B7-2 Monoclonal Antibody Treatment on the Development of Diabetes in the Nonobese Diabetic Mouse”, J. Exp. Med., vol. 181, pp. 1145-1155 (1995).
Lin et al. “Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents” Current Opinion in Chemical Biology, vol. 2, pp. 453-457 (1998).
Lynch et al. “TWEAK induces angiogenesis and proliferation of endothelial cells.” J Biol Chem. Mar. 26, 1999;274(13):8455-9.
Lynch et al., “Tweak Induces Proliferation in Endothelial Cells and Substitutes For EGF and Hydrocortisone in Culture”, Interferon Cytokine Res., vol. 18, A-46 (1998).
Mackay and Browning, “Turning off follicular dendritic cells”, Nature, vol. 395, pp. 26-27 (1998).
Marsters et al., “Identification of a ligand for the death-domain-containing receptor Apo3”, Current Biology, vol. 8, pp. 525-528 (1998).
Meighan-Mantha et al. “The Mitogen-inducible Fn14 Gene Encodes a Type I Transmembrane Protein that Modulates Fibroblast Adhesion and Migration” J. Biol. Chem., Nov. 1999; 274: 33166-33176.
Mohan et al., “Interaction Between CD40 and Its Ligand gp39 in the Development of Murine Lupus Nephritis1”, J. Immunol., vol. 154, pp. 1470-1480 (1995).
Nagata (1997) “Apoptosis by Death Factor” Cell 88:355-365.
Ngo et al., “Computational complexity, protein structure prediction, and the Levinthal paradox”, The Protein Folding Problem, Chapter 14, pp. 435-508 (1994).
Ruuls et al., “The Length of Treatment Determines Whether IFN-β Prevents or Aggravates Experimental Autoimmune Encephalomyelitis in Lewis Rats”,The Journal of Immunology, vol. 157, pp. 5721-5731 (1996).
Steinman, “Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year”The Journal of Experimental Medicine, vol. 197, No. 9, pp. 1065-1071 (2003).
Steinman and Zamvil
Biogen Idec MA Inc
Finnegan Henderson Farabow Garrett & Dunner LLP
Haddad Maher M
LandOfFree
Antagonists of TWEAK and of TWEAK receptor and their use to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of TWEAK and of TWEAK receptor and their use to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of TWEAK and of TWEAK receptor and their use to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4085871